Compare · BDX vs XENT
BDX vs XENT
Side-by-side comparison of Becton Dickinson and Company (BDX) and Intersect ENT Inc. (XENT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDX and XENT operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $41.65B, about 45.7x XENT ($911.2M).
- BDX has hit the wire 10 times in the past 4 weeks while XENT has been quiet.
- BDX has more recent analyst coverage (25 ratings vs 5 for XENT).
- Company
- Becton Dickinson and Company
- Intersect ENT Inc.
- Price
- $149.98-0.82%
- $28.25+0.02%
- Market cap
- $41.65B
- $911.2M
- 1M return
- -2.11%
- -
- 1Y return
- -13.04%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2014
- News (4w)
- 10
- 0
- Recent ratings
- 25
- 5
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Intersect ENT Inc.
Intersect ENT, Inc. operates as an ear, nose, and throat (ENT) medical technology company in the United States. The company offers PROPEL and PROPEL Mini, which are steroid releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It also provides SINUVA, a steroid releasing implant for the treatment of patients in the physician office setting; VENSURE Navigable and Stand-alone balloon, a sterile and single-use device, used to access and treat frontal, sphenoid sinus, and maxillary ostia in adults using a trans-nasal approach; and CUBE Navigation System, a virtual guidance platform for high precision ENT and ENT related skull-base surgeries. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was incorporated in 2003 and is headquartered in Menlo Park, California.
Latest BDX
- Chairman, CEO and President Polen Thomas E Jr exercised 20,209 shares at a strike of $126.16, returned $2,549,587 worth of shares to the company (17,445 units at $146.15) and sold $404,511 worth of shares (2,764 units at $146.35) as part of a pre-agreed trading plan, increasing direct ownership by 4% to 110,163 units (SEC Form 4)
- EVP and President, BDI Menziuso Peter was granted 14,258 shares (SEC Form 4)
- New insider Menziuso Peter claimed no ownership of stock in the company (SEC Form 3)
- Becton Dickinson and Company filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- EVP, Chief Revenue Officer Feld Michael sold $11,051 worth of shares (75 units at $147.35) as part of a pre-agreed trading plan, decreasing direct ownership by 0.35% to 21,084 units (SEC Form 4)
- SEC Form SD filed by Becton Dickinson and Company
- SEC Form CERT filed by Becton Dickinson and Company
- BD Delivers Kidney Stone Care for Urology Teams with the Elyra™ Thulium Fiber Laser System
- Becton Dickinson and Company filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- Peter Menziuso Named EVP and President, BD Interventional
Latest XENT
- FDA Approval for SINUVA issued to INTERSECT ENT INC
- SEC Form POSASR filed by Intersect ENT Inc.
- SEC Form RW WD filed by Intersect ENT Inc.
- Nalu Medical, Inc. Names Thomas West President and Chief Executive Officer
- SEC Form 15-12B filed by Intersect ENT Inc.
- SEC Form S-8 POS filed by Intersect ENT Inc.
- SEC Form EFFECT filed by Intersect ENT Inc.
- SEC Form 4 filed by Hattangadi Neil A
- SEC Form 4: Meier Richard A closing all direct ownership in the company
- SEC Form 4: Fernandez Reyna M closing all direct ownership in the company